U.S. Research Sites

The Novo Nordisk U.S. research centers are dedicated to the discovery and development of innovative biological medicines. With decades of experience in researching and developing proteins, we explore new research areas and continuously turn science and technologies into next generations of safe and effective biological medicines. In parallel, we design and develop innovative delivery devices based on patient insights.

We believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation. We work closely with patient organizations, healthcare professionals, universities, biotech companies and policymakers worldwide to bring about innovation. Producing lifesaving medicine is a significant responsibility: millions of people depend on us. This is why we combine our scientific expertise and deep disease understanding with the insight of how it is to live with a serious chronic disease. Only by considering what is valuable from a patient perspective can we help people live a life with as few limitations as possible.

Our Seattle facility

Novo Nordisk's research center located in Seattle is the epicenter of Novo Nordisk's research activities in the U.S. The unique concept behind the center is to combine basic research, early proof-of-concept trials and medical device research under one umbrella. Researchers have a mandate to pursue a translational research approach to finding new antigen-based immunological and vaccine treatment advances for type 1 diabetes and obesity and to identify game-changing devices to support treatments.

Established in 2009, the research center is focused on early discovery projects within the diabetes and obesity areas. Our scientists apply cutting-edge technologies to bring molecules to market. Right now, that means identifying protein-based therapies for obesity and diabetes prevention as well as diabetes treatment and research on the next generation of medical devices.

Economic impact

Drawn to Seattle for the city's reputation as a biotech hub, Novo Nordisk has invested more than $100 million in the facility since 2009. The center currently employs more than 100 people.
For the community

We are parents, colleagues, neighbors and friends—people living with the complexities of serious diseases. And we believe in the combination of science and soul to help nurture each other back to good health. We live this mission at Novo Nordisk every day to benefit patients, their families, as well as the broader community.

Novo Nordisk is committed to making a difference in Seattle through support for local organizations and partnerships with the Seattle biotech and academic communities that focus on early stage research projects.

Currently, we partner with the Benaroya Research Institute on diabetes studies. We are also working with JDRF and Pacific Northwest Research Institute to accelerate discovery and development of novel immunotherapies to prevent, treat and cure type 1 diabetes. We are also a sponsor of Shoreline Community College’s biotechnology program.

Clinical research partnerships

Clinical research and regulatory expertise bring medicines to patients. Bringing our molecules from research to patients requires about eight years of concerted effort involving many internal and external stakeholders. All through this rigorous development process, we engage in close dialogue with health authorities in order to document the efficacy, safety and optimal use of our medicines. We take pride in collaborating directly with local investigators at Washington health institutions to conduct our clinical trials, including the University of Washington, Endocrine and Diabetes Care Center; Providence Sacred Heart Medical Center and Children’s Hospital; and Wenatchee Valley Hospital & Clinics.

About Novo Nordisk in the U.S.:

Novo Nordisk, a global healthcare company, has been committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases, including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for success is to stay focused, think long term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in four states, Novo Nordisk employs nearly 6,000 employees throughout the country. For more information, visit novonordisk.us, Facebook, Twitter, and Instagram.

STAY CONNECTED

linkedin.com/company/novo-nordisk

For more information about Novo Nordisk’s Washington and Indiana locations, visit: novonordisk.us and select Seattle, WA and Indianapolis, IN under “US Locations.”

Sustainability

Novo Nordisk’s focus is to be a sustainable business. The Triple Bottom Line (TBL) principle is anchored in the way we do business, ensuring that our decisions balance financial, environmental and socially responsible considerations while always keeping in mind the best interests of the patients we serve.

Novo Nordisk’s research center in Seattle is involved in a variety of sustainability efforts, including:

- Collaborating with the city of Seattle to promote and encourage the use of green transportation options like bicycling to work, public transport and vanpool programs.
- Creating in-house recycling and sustainability programs, such as composting food waste; properly recycling pipette tip boxes and styrofoam, metals and computer equipment; and utilizing a chemical recycler and a glasswash system to clean all vessels and neutralize (remove chemicals) liquids before they enter the city’s waste system.

Indianapolis Research Center

Novo Nordisk Research Center Indianapolis, Inc. (NNRCl) was established in late 2015 when Novo Nordisk acquired Calibrium and MB2, two private companies co-founded by Dr. Richard DiMarchi that were focused on developing protein-based products for diabetes and obesity. Today, NNRCl is the home of an elite research team to further the success of Dr. DiMarchi’s work in union with Novo Nordisk’s global research efforts.

NNRCl is focused on early discovery projects within the diabetes and obesity areas. Our scientists apply cutting-edge technologies to bring molecules to market. Right now, that means identifying protein-based therapies for obesity and diabetes prevention, and diabetes treatment.